Emerging Therapies in Antiphospholipid Syndrome

Area of Science:

• Rheumatology
• Hematology
• Immunology

Background:

• Antiphospholipid syndrome (APS) is a prothrombotic condition linked to antiphospholipid antibodies.
• Current warfarin therapy for APS faces challenges in efficacy, safety, and patient adherence.
• Emerging research identifies new molecular targets for APS treatment.

Purpose of the Study:

• To review current and emerging therapeutic strategies for Antiphospholipid Syndrome (APS).
• To evaluate novel anticoagulants and immunomodulatory agents for APS management.
• To identify future research directions for APS treatment.

Main Methods:

• Comprehensive literature review of in vitro, animal, and clinical studies.
• Analysis of data on direct thrombin/Factor Xa inhibitors, hydroxychloroquine, statins, and biologics.
• Synthesis of information on targeted molecular therapies (NF-κB, p38 MAPK inhibitors).

Main Results:

• New oral anticoagulants (NOACs) show promise but require further validation.
• Immunomodulatory agents like hydroxychloroquine and biologics offer alternative pathways.
• Targeted therapies against specific molecules (e.g., complement, B cells) are under investigation.

Conclusions:

• Alternative treatments beyond warfarin are crucial for refractory APS and non-classical presentations.
• Further large-scale, prospective studies are essential to establish the efficacy and safety of novel APS therapies.
• Personalized treatment approaches targeting specific pathogenic mechanisms may improve outcomes in APS.